The Korea Food and Drug Administration(KFDA) recommends the use of a crossover design to assess the bioequivalence of generic drugs. However, a standard crossover design for bioequivalence trials is often considered problematic due to ethical and economic issues as highly variable drugs are usually required by large numbers of subjects when designing the trial. To overcome this problem a crossover design has been a recommended option as per US regulations; in addition, a crossover design has also recently drawn special attention as an efficient alternative. The current KFDA regulation requires an ANOVA table for every bioequivalence study; however, ANOVA tables of and crossover designs have never been published in the literature. This study shows the derivation of tables of analysis of variance for a cross-over design and a cross-over design. We also suggest a sample size formulas for , and crossover designs to provide information on the selection of efficient designs for highly variable drugs.
[1]
L. Endrenyi,et al.
Regulatory and study conditions for the determination of bioequivalence of highly variable drugs.
,
2009,
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[2]
Sang-Gue Park,et al.
On Evaluation of Bioequivalence for Highly Variable Drugs
,
2011
.
[3]
Donald J. Schuirmann.
A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability
,
1987,
Journal of Pharmacokinetics and Biopharmaceutics.
[4]
In-hwan Baek,et al.
Bioequivalence Approaches for Highly Variable Drugs: Issue and Solution
,
2009
.
[5]
S. Chow,et al.
Design and Analysis of Bioavailability and Bioequivalence Studies, The Third Edition
,
2008
.